Tecelra, developed by biopharmaceutical company Adaptimmune, is the first gene therapy treatment for adult patients with unresectable or metastatic synovial sarcoma to be approved by the FDA, according to an Aug. 2 news release from the agency.
Synovial sarcoma affects around 1,000 people in the U.S. every year and occurs most frequently with males in their 30s and younger.
Treatment for synovial sarcoma usually involves surgery or a combination of radiotherapy/chemotherapy and surgery for certain tumors or disease spread. Tecelra is administered in a single intravenous dose, the release said.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
